These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 9748568)

  • 1. DNA sequence selectivity of topoisomerases and topoisomerase poisons.
    Capranico G; Binaschi M
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):185-94. PubMed ID: 9748568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons.
    Capranico G; Binaschi M; Borgnetto ME; Zunino F; Palumbo M
    Trends Pharmacol Sci; 1997 Sep; 18(9):323-9. PubMed ID: 9345851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of new anti-cancer agents based on topoisomerase poisons targeted to specific DNA sequences.
    Arimondo PB; Hélène C
    Curr Med Chem Anticancer Agents; 2001 Nov; 1(3):219-35. PubMed ID: 12678755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iridoids as DNA topoisomerase I poisons.
    Gálvez M; Martín-Cordero C; Ayuso MJ
    J Enzyme Inhib Med Chem; 2005 Aug; 20(4):389-92. PubMed ID: 16206835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple helix-forming oligonucleotides conjugated to indolocarbazole poisons direct topoisomerase I-mediated DNA cleavage to a specific site.
    Arimondo PB; Bailly C; Boutorine AS; Moreau P; Prudhomme M; Sun JS; Garestier T; Hélène C
    Bioconjug Chem; 2001; 12(4):501-9. PubMed ID: 11459453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
    Fortune JM; Osheroff N
    Prog Nucleic Acid Res Mol Biol; 2000; 64():221-53. PubMed ID: 10697411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase I poisons and suppressors as anticancer drugs.
    Bailly C
    Curr Med Chem; 2000 Jan; 7(1):39-58. PubMed ID: 10637356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence-specific interactions of drugs interfering with the topoisomerase-DNA cleavage complex.
    Palumbo M; Gatto B; Moro S; Sissi C; Zagotto G
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):145-54. PubMed ID: 12084456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coralyne and related compounds as mammalian topoisomerase I and topoisomerase II poisons.
    Makhey D; Gatto B; Yu C; Liu A; Liu LF; LaVoie EJ
    Bioorg Med Chem; 1996 Jun; 4(6):781-91. PubMed ID: 8818227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs acting on DNA topoisomerases: recent advances and future perspectives.
    Gatto B; Capranico G; Palumbo M
    Curr Pharm Des; 1999 Mar; 5(3):195-215. PubMed ID: 10066890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes.
    Wilstermann AM; Osheroff N
    Curr Top Med Chem; 2003; 3(3):321-38. PubMed ID: 12570766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Poisons of DNA topoisomerases I and II].
    Charcosset JY; Soues S; Laval F
    Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between topoisomerase II inhibition, sequence-specificity and DNA binding mode of dicationic diphenylfuran derivatives.
    Bailly C; Dassonneville L; Carrasco C; Lucas D; Kumar A; Boykin DW; Wilson WD
    Anticancer Drug Des; 1999 Feb; 14(1):47-60. PubMed ID: 10363027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diversity of DNA topoisomerases I and inhibitors.
    Pommier Y
    Biochimie; 1998 Mar; 80(3):255-70. PubMed ID: 9615865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic sites of topoisomerase II activity determined by comparing DNA breakage enhanced by three distinct poisons.
    Borgnetto ME; Tinelli S; Carminati L; Capranico G
    J Mol Biol; 1999 Jan; 285(2):545-54. PubMed ID: 9878428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
    Tse-Dinh YC
    Infect Disord Drug Targets; 2007 Mar; 7(1):3-9. PubMed ID: 17346206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase-targeting antitumor drugs.
    D'Arpa P; Liu LF
    Biochim Biophys Acta; 1989 Dec; 989(2):163-77. PubMed ID: 2557085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents.
    Okoro CO; Fatoki TH
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of resistance to topoisomerases poisons.
    Prost S
    Gen Pharmacol; 1995 Dec; 26(8):1773-84. PubMed ID: 8745168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioassays and In Silico Methods in the Identification of Human DNA Topoisomerase IIα Inhibitors.
    Bergant K; Janezic M; Perdih A
    Curr Med Chem; 2018; 25(28):3286-3318. PubMed ID: 29508675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.